Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) EBITDA: 2016-2025

Historic EBITDA for Akebia Therapeutics (AKBA) over the last 9 years, with Sep 2025 value amounting to $540,000.

  • Akebia Therapeutics' EBITDA rose 102.69% to $540,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.9 million, marking a year-over-year increase of 65.42%. This contributed to the annual value of -$69.4 million for FY2024, which is 33.67% down from last year.
  • Per Akebia Therapeutics' latest filing, its EBITDA stood at $540,000 for Q3 2025, which was up 118.62% from $247,000 recorded in Q2 2025.
  • Akebia Therapeutics' 5-year EBITDA high stood at $29.4 million for Q2 2022, and its period low was -$83.0 million during Q2 2021.
  • For the 3-year period, Akebia Therapeutics' EBITDA averaged around -$10.4 million, with its median value being -$11.2 million (2023).
  • In the last 5 years, Akebia Therapeutics' EBITDA spiked by 135.46% in 2022 and then slumped by 3,814.01% in 2024.
  • Over the past 5 years, Akebia Therapeutics' EBITDA (Quarterly) stood at -$69.9 million in 2021, then soared by 91.31% to -$6.1 million in 2022, then spiked by 110.11% to $614,000 in 2023, then tumbled by 3,814.01% to -$22.8 million in 2024, then soared by 102.69% to $540,000 in 2025.
  • Its EBITDA was $540,000 in Q3 2025, compared to $247,000 in Q2 2025 and $6.1 million in Q1 2025.